Dubai: The Emirates Drug Establishment (EDE) has announced the registration of Blenrep (Belantamab Mafodotin) as an ...

GSK (GSK.L) expects to deliver annual sales and profit growth towards the top end of its forecasts after beating ...

Blenrep approved in the EU for multiple myeloma | Regulatory NewsThe approval is based on superior efficacy results demonstrated by Blenrep combinations in the pivotal DREAMM-7 and DREAMM-8 phase ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking to its projection to generate sales of more than 40 billion pounds sterling ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter expectations on Wednesday, in a boost to its efforts to fuel growth despite ...

UK-listed pharmaceutical company plans to bring four more speciality medicines to late-stage clinical trials this year ...

SALES FORECAST: The U.K. pharmaceutical company is expected to report sales of 7.8 billion pounds ($10.42 billion), according to consensus estimates compiled by the company. For last year's second ...

London: GSK plc has received approval for Blenrep in the European Union (EU) for the treatment of adults with relapsed or refractory multiple myeloma in combination with bortezomib plus ...

The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including Switzerland and Canada.